You searched for "cancer"
The urologist’s tale
In this series of articles I am going to show you some of the exhibits contained in the Museum of Urology, hosted on the BAUS website (www.baus.org.uk). The Canterbury Tales, written by Geoffrey Chaucer (c.1340’s-1400) in the 14th Century, is...New senior appointments at The Urology Foundation
The Urology Foundation (TUF) has appointed Rebecca Porta as Chief Executive. An established and experienced charity Chief Executive, Rebecca brings a wealth of experience having held senior roles within some of the UK’s leading health and medical research charities.
Multiparametric MRI with targeted-only biopsy – a new standard?
In this issue of European Urology, Kasivisvanathan et al. present a meta-analysis of two randomised trials comparing prebiopsy MRI with targeted biopsy (TBx) alone versus standard transrectal ultrasound-guided biopsy (TRUS-Bx) in biopsy-naïve men at risk of prostate cancer. Their findings...
Refining management of non-visible haematuria
The optimal evaluation of non-visible haematuria (NVH) continues to be debated, with competing interests of avoidance underdiagnosis and the harms of over-testing. Current National Institute for Health & Care Excellent (NICE) guidance recommends referral for patients ≥60 years with NVH....
PSA screening in limbo: how low should we go?
One may wonder how the management of prostate cancer could have evolved differently if it had followed a path similar to breast cancer. In breast cancer, early detection in the 1970s relied heavily on imaging because no reliable circulating biomarker...BBS Revolution™ bladder scanner
Featuring a wireless scanning probe with eight ultrasound transducers for fully automatic bladder detection, BBS Revolution™ differentiates between male / female anatomy, delivering accurate volume measurements in seconds. Simple to use BBS Revolution™ is for...Consensus statements on PSA testing in asymptomatic men in the UK
In January 2016, the UK National Screening Committee once again recommended against a systematic population screening programme for prostate cancer due to the, as yet, insufficient evidence that the benefits of screening would outweigh the harm to the population as...In conversation with Rebecca Porta
We were delighted to chat to Rebecca Porta, the new Chief Executive of The Urology Foundation (TUF) First of all, many congratulations on your recent appointment as Chief Executive of TUF; can you tell us a little bit about your...The PROMIS trial – time for multi-parametric MRI before a first prostate biopsy
Whilst the relatively random process of 12 core transrectal ultrasound guided (TRUS) prostate biopsy remains by far the most widely employed approach to prostate cancer diagnosis in the UK, its flaws as a standalone diagnostic strategy are increasingly apparent. TRUS-biopsy...
Prostate biopsy and survival
Talk to many urologists and the axiom is “you are more likely to die with prostate cancer than from it”. This study was conducted on Danish men between 1995 and 2011. The observations are: 1) Cumulative prostate cancer – specific...
The survival impact of neoadjuvant hormonal therapy before radical prostatectomy
There is increasing evidence for the role of radical prostatectomy in select patients with T3-T4 prostate cancer (as part of multimodal therapy). This retrospective multicentre study explored the benefit of neoadjuvant hormonal therapy before radical prostatectomy specifically in patients with...
